PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

Recruiting

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(14 sites)

Canada

University of Calgary, Cumming School of Medicine, O'Brien Institute for Public Health, Calgary, Alberta

Surrey Memorial Hospital - Fraser Health Authority, Surrey, British Columbia

Eastern Health, St. John's, Newfoundland and Labrador

Kingston General Hospital, Kingston, Ontario

Jewish Genral Hospital, Montreal, Quebec